Compare SPRU & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPRU | NRXS |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Auto Parts:O.E.M. | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.0M | 78.9M |
| IPO Year | 2019 | 2023 |
| Metric | SPRU | NRXS |
|---|---|---|
| Price | $3.48 | $7.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 42.4K | ★ 154.2K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.30 | 22.13 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $23,194,000.00 | $3,569,282.00 |
| Revenue This Year | N/A | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 48.68 | 32.89 |
| 52 Week Low | $1.13 | $1.94 |
| 52 Week High | $6.75 | $8.40 |
| Indicator | SPRU | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 34.16 | 57.08 |
| Support Level | $3.44 | $6.58 |
| Resistance Level | $4.30 | $7.85 |
| Average True Range (ATR) | 0.23 | 0.53 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 11.76 | 55.91 |
Spruce Power Holding Corp is an owner and operator of distributed solar energy assets across the United States (the U.S.), offering subscription-based services to home solar assets and customer contracts, making renewable energy more accessible to everyone. The Company's customers are homeowners and the Company's core solar service offerings generate revenues through, the sale of electricity generated by its home solar energy systems to homeowners, third-party contracts to sell solar renewable energy credits (SRECs) generated by the solar energy systems for fixed prices and the servicing of those agreements for other institutional owners of home solar energy systems.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).